SV investment has resulted in the approval of 24 novel therapeutics
SV News
31 March 2020Portfolio NewsSV Health Investors Announces Licensing and Research Collaboration between Sitryx and Lilly to Discover and Develop New Immunometabolic Medicines- 26 March 2020Portfolio NewsSutroVax Announces $110M Series D Financing to Advance Broadest-Spectrum Pneumococcal Vaccine Candidates to Prevent Pneumonia
16 March 2020Portfolio NewsAVROBIO Reports Fourth Quarter and Fiscal Year 2019 Financial Results and Provides Business Update- 12 March 2020Portfolio NewsSutro Biopharma Announces Extension of First Cytokine Derivative Research Program Under Collaboration with Merck
10 March 2020Portfolio NewsBicycle Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Corporate Updates- 9 March 2020Portfolio NewsAVROBIO Receives Orphan Drug Designation from U.S. FDA for AVR‑RD‑04 for Cystinosis
- 9 March 2020Portfolio NewsDeciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2019 Financial Results
4 March 2020Portfolio NewsSV Health Investors joins Xilio Therapeutics’ $100.5 million Series B financing - proceeds will advance XTX201 and XTX101 into the clinic while expanding Xilio’s cytokine pipeline
2 March 2020Portfolio NewsEvelo Biosciences Announces Biomarker Data Showing EDP1815 is an Orally Delivered Dual Cytokine Inhibitor for Inflammatory Diseases- 2 March 2020Portfolio NewsAkrevia Therapeutics Rebrands as Xilio Therapeutics and Announces $100.5 Million Series B Financing
- 25 February 2020Portfolio NewsBicycle Therapeutics Announces Exclusive Strategic Collaboration with Genentech to Develop and Commercialize Bicycle®-based Immuno-oncology Therapies
- 7 January 2020Portfolio NewsBicycle Therapeutics and Cancer Research UK to Collaborate on Development of New Bicycle® Immuno-oncology Candidate, BT7401
